Home About us Contact
|
Home About us Contact | ||
|
|
||
Drug Formulations (drug + formulations)
Selected AbstractsInfluence of administration vehicles and drug formulations on the pharmacokinetic profile of lamotrigine in ratsFUNDAMENTAL & CLINICAL PHARMACOLOGY, Issue 5 2002M. M. Castel-Branco Abstract Given that administration vehicles and drug formulations can affect drug bioavailability, their influence on the pharmacokinetic profile of lamotrigine (LTG), a new-generation anti-epileptic drug, was studied in rats. Three different formulations administered intraperitoneally at a dose of 10 mg/kg were used: (1) LTG suspended in a 0.25% methylcelulose solution, (2) LTG dissolved in a 50% propylene glycol solution, and (3) LTG isethionate dissolved in distilled water. Plasma and brain homogenate levels were determined in order to evaluate vehicle-dependent drug absorption. The results demonstrated rapid absorption of LTG when it was administered as an aqueous solution, in contrast to a slower and more erratic absorption after the injection of either the lipophilic solution or the suspension. A plasma peak was achieved 15 min post-dose with the aqueous solution, with a brain peak being achieved 15 min later, while with the other formulations both plasma and brain homogenate peaks were reached 2 h after LTG administration. This study suggests that LTG isethionate dissolved in distilled water is the most suitable formulation for successful LTG pharmacokinetic studies in rats. [source] Development of an Artificial Lipid-Based Membrane Sensor with High Selectivity and Sensitivity to the Bitterness of Drugs and with High Correlation with Sensory ScoreIEEJ TRANSACTIONS ON ELECTRICAL AND ELECTRONIC ENGINEERING, Issue 6 2009Yoshikazu Kobayashi Non-member Abstract This paper reports the development of membrane sensors based on an artificial lipid and plasticizers with high selectivity and sensitivity to drug bitterness by using bis(1-butylpentyl) adipate (BBPA), bis(2-ethylhexyl) sebacate (BEHS), phosphoric acid tris(2-ethylhexyl) ester (PTEH), and tributyl o-acetylcitrate (TBAC) as a plasticizer and phosphoric acid di-n-decyl ester (PADE) as an artificial lipid to optimize surface hydrophobicity of the sensors. In addition, a sensor with highly correlated bitterness sensory score was developed by blending BBPA and TBAC to detect the bitterness suppression effect of sucrose, and other bitter-masking materials. Therefore, this sensor can be used to evaluate the bitterness of various drug formulations with high accuracy. Copyright © 2009 Institute of Electrical Engineers of Japan. Published by John Wiley & Sons, Inc. [source] Relative oral bioavailability of microgranulated amoxicillin in pigsJOURNAL OF VETERINARY PHARMACOLOGY & THERAPEUTICS, Issue 5 2002P. Anfossi A new microgranulated formulation of amoxicillin trihydrate for in-feed medication was developed using a lipogelled matrix. Its relative bioavailability was compared with powdered drug in pigs and an assessment was made to determine whether therapeutic concentrations were achieved. Microgranules containing 10% (MICR10) and 30% (MICR30) amoxicillin and free amoxicillin trihydrate powder (reference, AMX) were administered at dosages of 50 mg of amoxicillin/kg b.w. using a three-way-crossover design. Amoxicillin analysis in serum was performed by a sensitive high performance liquid chromatography (HPLC) method with fluorometric detection, using an extraction procedure already described for edible tissues of fish and adapted and validated for pig serum. The oral bioavailability of both microgranulated formulations was higher than that of the reference formulation [relative bioavailability (F): 153.9 ± 58.2% for MICR10; 126.2 ± 70.5% for MICR30] and the area under the concentration,time curve (AUC) values of MICR10 and AMX formulations were significantly different (P < 0.05). Differences between the mean maximum concentration (Cmax), time of Cmax (tmax) and mean residence time (MRT) of the drug formulations were not significant. Microgranulated amoxicillin is suitable for in-feed administration to pigs and, because of its higher oral bioavailability compared with the powdered compound, it may be more effective for the treatment of susceptible infections. [source] Review article: new drug formulations, chemical entities and therapeutic approaches for the management of ulcerative colitisALIMENTARY PHARMACOLOGY & THERAPEUTICS, Issue 7 2008S. C. NG Summary Background, Treatment options for ulcerative colitis (UC) are expanding with the development of novel drug formulations and dosing regimens and new chemical entities. Although the goals of medical therapy for UC remain unchanged, that is to induce and to maintain remission, focus has also centred on improving patient compliance, modifying the natural course of disease and healing the mucosa. Aim, To examine novel formulations, new chemical entities and novel therapeutic approaches to the management of UC. Methods, Searches for all studies related to UC treatment in Medline and abstracts from major national and international meetings published in the last 10 years. Results, 5-Aminosalicylic acids (5-ASA) remain the standard first-line treatment for patients with mild to moderately active UC. New formulations with altered delivery, and new dosing regimens have demonstrated possible improvements in efficacy compared with historically available preparations and dosing patterns. Once-daily dosing, micropellet formulations, and high-dose tablets offer enhanced efficacy and improved compliance. 5-ASA is now recognized as a ligand for peroxisome proliferator-activated receptor-, (PPAR-,) and it has a role as a chemo-preventive agent in long-standing UC. New colonic release corticosteroid formulations help to limit systemic toxicity; turmeric, tacrolimus and infliximab have shown promising results. New anti-inflammatory targeted therapies include an anti-CD3 antibody, selective integrin blockers, anti-IL-2 antibody and PPAR-, agonists. Conclusion, The evolution of novel oral 5-ASA formulations and dosage regimens, and recent development of new molecules have expanded the therapeutic armamentarium of UC. [source] High-pressure NMR characterization of triacetyl-,-cyclodextrin in supercritical carbon dioxideMAGNETIC RESONANCE IN CHEMISTRY, Issue 2 2009G. I. Ivanova Abstract Cyclodextrins are used in many drug formulations since their cavities provide microenvironments where drug molecules can enter and form inclusion complexes for controlled drug delivery. Supercritical carbon dioxide (scCO2) is an alternative to organic solvents and a very attractive medium for the preparation of these inclusion complexes. The potential ability of triacetyl-,-cyclodextrin (TA-,-CD) to form inclusion complexes in addition to its high miscibility in liquid and scCO2 could offer a chance for an economical and environmental friendly chemical processing. In this work, high-pressure NMR studies were performed in order to obtain information on the molecular structure and dynamics of TA-,-CD in scCO2 at 313.15 K and 20 MPa and its ability to form inclusion complexes under these conditions was studied. The influence of scCO2 on a number of NMR spectral parameters, such as chemical shifts, spin-spin coupling constants, nuclear Overhauser effect (NOE) and spin-lattice relaxation (T1) has been studied. We unequivocally show for the first time structural changes of TA-,-CD in scCO2, like acetyl chain orientation and overall shape distortions that can affect its inclusion capability in this medium. The possibility of cavity self-closure is discussed and the results of two inclusion studies that support cavity self-closure, with the angiotensin-converting enzyme inhibitor, captopril, and the nonsteroid anti-inflammatory drug, flufenamic acid, are presented. Copyright © 2008 John Wiley & Sons, Ltd. [source] A Point Estimator for the Time Course of Drug ReleaseBIOMETRICAL JOURNAL, Issue 1 2009Stephan Koehne-Voss Abstract Procedures for deconvolution of pharmacokinetic data are routinely used in the pharmaceutical industry to determine drug release and absorption which is essential in designing optimized drug formulations. Although these procedures are described extensively in the pharmacokinetic literature, they have been studied less from a statistical point of view and variance estimation has not been addressed. We discuss the statistical properties of a numerical procedure for deconvolution. Based on a point-area deconvolution method we define an estimator for the function that describes the time course of drug release from a drug formulation. Asymptotic distributions are derived and several methods of variance and interval estimation are compared (© 2009 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim) [source] Commercial taxane formulations induce stomatocytosis and increase blood viscosityBRITISH JOURNAL OF PHARMACOLOGY, Issue 6 2001Michael Mark Taxanes are antineoplastic drugs which have cardiovascular side effects of unknown mechanism. We investigated their influence on blood viscosity and erythrocyte morphology. Whole blood was incubated in vitro with increasing concentrations of Taxol®, Taxotere®, paclitaxel (0 , 100 ,M) and the vehicles Cremophor-EL and Tween 80 (0 , 5% vol) for 1 h at 37°C. Plasma and whole blood viscosity (Haematocrit 45%) were measured and erythrocyte morphology was assessed on glutaraldehyde-fixed cells. The same investigations were performed in seven patients before and after a Taxol®-infusion. Taxol® and Taxotere® induced a dose- and time-dependent stomatocytic shape transformation of erythrocytes. Paclitaxel alone had no effect, but the vehicles cremophor-EL and Tween 80, used in Taxol® and Taxotere®, respectively, induced a comparable degree of stomatocytosis. This suggests a preferential intercalation of these substances into the inner hemileaflet of the membrane lipid bilayer. Associated with this shape change a dose-dependent increase in plasma and whole blood viscosity was observed. Neither shape nor viscosity changes were reversible upon removal of the agents. After the infusion of 130 , 300 mg Taxol® in patients a slight shift towards stomatocytosis and an increase in whole blood viscosity at high shear rate from 5.09±0.30 to 5.44±0.38 mPa.s (P<0.05) were confirmed. Commercial taxane drug formulations induce stomatocytosis and increase blood viscosity, which is due to their formulation vehicles. These findings may contribute to the understanding of the cardiovascular side effects of these drugs. British Journal of Pharmacology (2001) 134, 1207,1214; doi:10.1038/sj.bjp.0704387 [source] | ||||||||||